News
NICE recommends Rinvoq to treat severe Rheumatoid Arthritis.- AbbVie
The National Institute for Health and Care Excellence (NICE) has recommended Rinvoq (upadacitinib) from AbbVie together with standard-of-care methotrexate, for coverage on the National Health Service as a treatment for severe rheumatoid arthritis, according to draft guidance.
Rinvoq, with a list price of £805.56 ($1,058.06) per 28-day pack and average annual cost per patient of £10,508 ($13,801), will come with a confidential discount. Despite the success in severe RA, NICE did not accept Rinvoq's application to treat moderate RA, stating that the drug's price didn't meet its cost-effectiveness standard in that indication.
Condition: Rheumatoid Arthritis
Type: drug